← All Galapagos NV filings

Galapagos NV 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
GLPG
Galapagos NV
20-F: Galapagos Pivots to BD, Exits Cell Therapy, Boosts Cash
Galapagos NV announced a significant strategic shift, winding down its cell therapy operations and small molecule discovery programs to focus on business development-led pipeline expansion in oncology and immunology, backed by a strong cash position.
NASDAQ
GLPG
Galapagos NV
20-F: Galapagos NV Files 20-F Report: Details Financial Performance and Corporate Governance
Galapagos NV releases its annual report on Form 20-F, providing a comprehensive overview of the company's financial results, operations, and corporate governance for the fiscal year ended December 31, 2024.
NASDAQ
GLPG
Galapagos NV
20-F: Galapagos NV Implements 2023 Compensation Recovery Policy
Galapagos NV adopts a policy to recover erroneously awarded compensation from executive officers following financial restatements, aligning with SEC and Nasdaq rules.